country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-184928

Copy Link Print Information

S34-1040

S34-1040 is an AKR1C3 inhibitor with a human IC₅₀ of 0.03 μM and exhibits no detectable inhibition of AKR1C1, AKR1C2, or AKR1C4. S34-1040 functions as a chemosensitizer and restores sensitivity of doxorubicin-resistant breast cancer cells to doxorubicin. S34-1040 can be used for the research of doxorubicin-resistant breast cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 3099381-90-2
Formule: C₁₈H₁₇N₃O₂
Masse moléculaire:307.35

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

S34-1040 Chemical Structure

CAS No.: 3099381-90-2

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]

AKR1C3

0.03 μM (IC₅₀)

Voir tous les produits spécifiques à Isoform 17β-HSD :

17β-HSD5/AKR1C3

In Vitro

OthersAnti-cancer

Others

S34-1040 potently and selectively inhibits recombinant AKR1C3 with an IC₅₀ of 0.03 μM, and exhibits over 2500-fold selectivity over the structurally related AKR1C1, AKR1C2 and AKR1C4 isoforms^[1].

Anti-cancer

S34-1040 (0-100 μM; 72-96 h) alone does not inhibit the proliferation of MCF-7/DOX cells even at a concentration as high as 100 μM. However, when treated with a protocol of 10-50 μM pre-incubation for 24 h followed by combined treatment for 72 h, it exerts strong synergistic effects with Doxorubicin (HY-15142A) to restore chemosensitivity, with a combination index (CI) ranging from 0.176 to 0.562^[1].
Combined treatment with S34-1040 (10 μM; 14 days) and Doxorubicin completely inhibits long-term colony formation of MCF-7/DOX cells, whereas S34-1040 alone has no effect on clonogenic growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

doxorubicin-resistant MCF-7/DOX breast cancer cells
Concentration:

0, 5, 10, 25, 40, 60, 80, 100 μM (single-agent); 0, 10, 25, 50 μM μM (combination with 0, 10, 25, 50 μM Doxorubicin)
Incubation Time:

72-96 h (single-agent); 24 h pre-incubation, followed by 72 h co-treatment (combination)
Result:

Showed weak antiproliferative activity even at concentrations up to 100 μM, with good cellular safety as a single agent.
Produced significantly stronger antiproliferative effects than Doxorubicin alone across all tested concentrations when combined with Doxorubicin.
Demonstrated strong to very strong synergy between S34-1040 and doxorubicin, with combination index (CI) values ranging from 0.176 to 0.562.

Cell Proliferation Assay^[1]

Cell Line:

doxorubicin-resistant MCF-7/DOX breast cancer cells
Concentration:

10 μM (single-agent); 10 μM combined with 25 μM Doxorubicin
Incubation Time:

14 days
Result:

Significantly suppressed the colony-forming ability of MCF-7/DOX cells, with no visible colonies remaining when combined with Doxorubicin.
Showed no significant difference compared to the blank control when used alone.
Saw doxorubicin alone at 25 μM fail to completely inhibit colony formation.

Related Protocols :

Breast Cancer Modeling

Chemical Information

CAS No. 3099381-90-2
Masse moléculaire 307.35
Formule C₁₈H₁₇N₃O₂
SMILES

N#CC1=CC=C(C=C1)CN(C)C(C2=CC(C(C3CC3)=O)=CN2)=O
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Instruction de manipulation (2659 KB)

Références

[1]. Qiao L, et al. Target-driven machine learning-enabled virtual screening (TAME-VS) enables prioritization of AKR1C3 inhibitors. Communications chemistry. 2026 Jun 15. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

S34-1040

Voir tous les produits spécifiques à Isoform 17β-HSD

Activité biologique

Description

IC50 & Target

In Vitro

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

S34-1040 Related Classifications

HY-184928 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target